Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: interim returned 17 record(s)
|
|
Monday, 07/30/2018
|
Formulation of Data Monitoring Committee Recommendations for Adaptive Design Clinical Trials
Navneet Hakhu, Axio Research
8:50 AM
|
A Parametric Multiple Comparison Procedure for Clinical Trials with Planned Evaluation of Treatment Effect in Pre-Defined Subgroups and Interim Analyzes
Liang Fang, MyoKardia; Ron Yu, Gilead Sciences, Inc.; Zhishen Ye, Gilead Sciences; Neby Bekele, Gilead Sciences; Ming Lin, Gilead Sciences
3:05 PM
|
Predictive Probability on Interim Analysis of Time-To-Event Endpoints with Delayed Treatment Effects
Matt Rosales, Astellas; Kentaro Takeda, Astellas Pharma Global Development, Inc.
3:35 PM
|
|
Tuesday, 07/31/2018
|
Endpoint and Time-To-Event Analyzes in Interim Clinical Trial Reports
Scott Diegel, University of Wisconsin-Madison; Ryan Zea, University of Wisconsin-Madison; Melissa Schultz, University of Wisconsin-Madison
|
Response to Regulatory Issues in an Adaptive Medical Device Study
Jill Stankowski, ICON Plc
|
Conditional Power Calculation for the Interim Monitoring of Cluster-Randomized Trials with Interval-Censored Endpoints
Kaitlyn Cook, Harvard University; Rui Wang, Harvard Pilgrim HealthCare Institute
|
Conditional Power Calculation for the Interim Monitoring of Cluster-Randomized Trials with Interval-Censored Endpoints
Kaitlyn Cook, Harvard University; Rui Wang, Harvard Pilgrim HealthCare Institute
9:00 AM
|
A Model-Based Conditional Power Assessment for Decision Making in Randomized Controlled Trial Studies
Baiming Zou, University of Florida; Jianwen Cai, University of North Carolina; Gary G. Koch, University of North Carolina; Haibo Zhou, University of North Carolina; Fei Zou, University of North Carolina at Chapel Hill
9:20 AM
|
|
Wednesday, 08/01/2018
|
Confessions of an Independent DMC Statistician
Brian Cohen, ACI Clinical
|
Incorporating Intermediate Binary Responses into Interim Analysis of a Long-Term Binary Endpoint
Andrejus Parfionovas, Takeda Pharmaceuticals; Jingjing Chen, Takeda Pharmaceuticals; Tina Liu, Takeda Pharmaceuticals; Cong Han, Takeda Pharmaceuticals; Xiaopan Yao, Takeda Pharmaceuticals
|
Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.
|
BLINDED SAMPLE SIZE RE-ESTIMATION
Chien-Hua Wu, Chung-Yuan Christian University; Shu-Mei Wan, Lunghwa University of Science and Technology
9:05 AM
|
Incorporating Intermediate Binary Responses into Interim Analysis of a Long-Term Binary Endpoint
Andrejus Parfionovas, Takeda Pharmaceuticals; Jingjing Chen, Takeda Pharmaceuticals; Tina Liu, Takeda Pharmaceuticals; Cong Han, Takeda Pharmaceuticals; Xiaopan Yao, Takeda Pharmaceuticals
9:10 AM
|
A Model-Based Approach for Simulating Adaptive Clinical Studies with Surrogate Endpoints Used for Interim Decision-Making
Xiaotian Chen, AbbVie; Alan Hartford, AbbVie Inc; Mei Li, AbbVie; Jun Zhao, AbbVie
9:20 AM
|
Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.
9:45 AM
|
|
|
